SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 15, 2011
Cardiovascular Systems, Inc.
(Exact name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
(State or Other Jurisdiction of Incorporation)
| 000-52082 (Commission File Number) |
41-1698056 (IRS Employer Identification No.) |
651 Campus Drive
St. Paul, Minnesota 55112-3495
(Address of Principal Executive Offices and Zip Code)
St. Paul, Minnesota 55112-3495
(Address of Principal Executive Offices and Zip Code)
(651) 259-1600
(Registrant’s telephone number, including area code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
Effective February 15, 2011, James E. Flaherty, our Chief Administrative Officer and Secretary,
adopted a pre-arranged trading plan (the “Trading Plan”) to sell shares of our common stock. The
Trading Plan was designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as
amended, and our policies regarding stock transactions. Under Rule 10b5-1, directors, officers and
other persons who are not in possession of material non-public information may adopt a pre-arranged
plan or contract for the sale of a registrant’s securities under specified conditions and at
specified times to achieve prudent and gradual asset diversification over time.
The Trading Plan provides that Mr. Flaherty will sell shares held by him personally over
approximately two and one-half years beginning March 14, 2011. The Trading Plan allows for the
sale of (i) 58,008 shares of common stock already owned by Mr. Flaherty, and (ii) an indeterminate
number of shares of common stock to be used to pay the required withholding taxes and transaction
costs associated with the vesting of restricted stock held by Mr. Flaherty. All shares will be
sold under the Trading Plan in the open market at prevailing market prices, subject to minimum
price thresholds and vesting restrictions. Mr. Flaherty will have no control over the actual
timing of the stock sales under the Trading Plan. Sales pursuant to the Trading Plan are expected
to begin as early as March 14, 2011 and will terminate no later than September 3, 2013, unless
terminated sooner in accordance with the Trading Plan’s terms.
All stock sales under the Trading Plan will be disclosed publicly in accordance with applicable
securities laws, rules and regulations through appropriate filings with the U.S. Securities and
Exchange Commission.
We do not undertake to report other Rule 10b5-1 plans that may be adopted by any of our officers or
directors in the future, or to report any modifications or termination of any publicly announced
plan or to report any plan adopted by an employee who is not an executive officer, except to the
extent required by law.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 22, 2011
| CARDIOVASCULAR SYSTEMS, INC. |
||||
| By: | /s/ Laurence L. Betterley | |||
| Laurence L. Betterley | ||||
| Chief Financial Officer | ||||